Pfizer advanced breast cancer drug gets China ok

Aug 10, 2018

The China National Drug Administration has granted approval of Pfizer’s Ibrance, the world's first CDK 4/6 selective inhibitor, effectively prolonging the median progression-free survival by 10 months.

The five-year survival rate of advanced breast cancer patients is only 20 percent, and no significant improvement in treatment solutions has been made in the past 10 years, reports BioSpectrum Asia

Ibrance, one of Pfizer’s fastest-growing blockbusters, has been approved for market entry in 86 countries and regions worldwide, and China mainland is the 87th.